Latest news about Jeevan Scientific Technology
Jeevan Scientific Technology
83.26
-1.10(-1.30%)
Company Performance:
View Company Insights1D-1.30%
1M+2.17%
6M+35.49%
1Y+106.45%
5Y-8.91%
More news about Jeevan Scientific Technology
07Jan 26
Padmaja Private Trust Acquires 7.53% Stake in Jeevan Scientific Technology
Padmaja Private Trust has acquired a substantial 7.53% stake in Jeevan Scientific Technology Limited through preferential allotment of 15 lakh equity shares worth Rs 6 crore. The acquisition, completed on January 2, 2026, triggered SEBI disclosure requirements under Regulation 29(1) as the trust crossed the substantial acquisition threshold. This forms part of the company's successful Rs 30.74 crore capital raising initiative, which will fund expansion plans including API/formulation unit acquisitions and working capital requirements.
07Jan 26
Jeevan Scientific Promoters Acquire 30L Warrants in Preferential Allotment
Jeevan Scientific Technology's four promoters collectively acquired 30,00,000 convertible warrants through preferential allotment, with Krishna Kishore Kuchipudi leading at 12,00,000 warrants. The acquisitions increase the company's equity capital to ₹19.92 crores and provide potential diluted capital expansion to ₹23.42 crores upon conversion.
18Dec 25
Jeevan Scientific Acquires 60% Stake in Naya Pharma for ₹10 Cr
Jeevan Scientific Technology Limited has acquired a 60% stake in Naya Pharma Private Limited for ₹10 crores. The acquisition, funded through a preferential issue, aims to expand Jeevan Scientific's presence in the pharmaceutical sector. Naya Pharma, incorporated in 2020, specializes in manufacturing and trading pharmaceutical ingredients. The transaction is classified as a related party deal due to common shareholders and directors between the two companies.
12Nov 25
Jeevan Scientific Technology Limited Shareholders Approve Key Resolutions in EGM
Jeevan Scientific Technology Limited (JSTL) held an Extraordinary General Meeting on November 12, 2025, where shareholders approved four significant resolutions. These include adopting a new Memorandum of Association, increasing authorized share capital from Rs. 21 crore to Rs. 25 crore, issuing convertible warrants to promoters and non-promoters, and issuing equity shares to non-promoters. All resolutions passed with over 99% votes in favor, indicating strong shareholder support for potential growth and structural changes within the company.
12Nov 25
Jeevan Scientific Technology Reports Net Loss in Q2 Amid Revenue Decline
Jeevan Scientific Technology Limited reported a consolidated net loss before tax of ₹369.90 lakhs for the half year ended September 30, compared to a profit of ₹5.07 lakhs in the previous fiscal year. Standalone net loss before tax was ₹268.56 lakhs. Despite losses, cash and cash equivalents increased to ₹77.42 lakhs from ₹20.59 lakhs. Total assets rose to ₹8,380.67 lakhs, while current liabilities significantly increased to ₹7,345.27 lakhs. The company's subsidiary, Nayas Laboratories, contributed positively with a net profit after tax of ₹9.50 lakhs for the quarter.
08Nov 25
Jeevan Scientific Technology Completes US FDA Remote Evaluation Successfully
Jeevan Scientific Technology Limited successfully completed a Remote Interactive Evaluation (RIE) by the US FDA for its Clinical Pharmacology facility. The evaluation, conducted from October 17 to November 6, 2025, covered BA/BE studies, operations, systems, and procedures, concluding with no critical observations. This outcome demonstrates the company's adherence to regulatory standards and may enhance its credibility in the pharmaceutical research sector.
15Oct 25
Jeevan Scientific Technology Unveils Rs. 30.74 Crore Capital Raising Plan
Jeevan Scientific Technology Limited (JSTL) has approved a capital raising plan of Rs. 30.74 crore through convertible warrants and equity shares. The plan includes issuing 35,00,000 convertible warrants at Rs. 40 per warrant and 41,85,000 equity shares at Rs. 40 per share. The warrants will be allotted to both promoters and non-promoters, while the equity shares are exclusively for non-promoters. The company also plans to increase its authorized share capital from Rs. 21 crore to Rs. 25 crore. An Extraordinary General Meeting is scheduled for November 12, 2025, to seek shareholder approval. Post-allotment, promoters' holding is expected to be 38.37%, with public holding at 61.63%.
Industry Peers
Syngene International
Indegene
Suven Life Sciences
Vimta Labs
Take SolutionsJeevan Scientific Technology
Bilcare
Adeshwar Meditex
Vanta Bioscience
442.00
(-4.00%)
521.55
(+0.51%)
279.34
(+4.56%)
469.70
(+2.85%)
30.80
(-0.42%)
83.26
(-1.30%)
62.20
(-0.43%)
18.41
(0.0%)
23.23
(-4.99%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
